QMS Medical Allied Services reports ₹2.44 crore Q2 FY27 profit
Key highlights
- QMS Medical reported Q2 FY27 revenue of ₹52.52 crore, up 17.5% year on year.
- Q2 FY27 net profit was ₹2.44 crore, down 31.8% from ₹3.58 crore in Q2 FY26.
- Operating margin declined to 12.41% from 15.48% a year earlier.
- QMS Medical has indicated an FY27 revenue objective of around ₹220 crore.
powered by IRIS

QMS Medical Allied Services Limited reported a consolidated net profit of ₹2.44 crore for Q2 FY27, down 31.8% from the year-ago quarter, even as revenue rose 17.5% year on year to ₹52.52 crore. The result matters because operating profit and margins also declined from both the preceding and year-ago quarters.
Know QMS Medical Allied Services inside out
Results, valuation, peers and who's buying, in one view.
What did QMS Medical report for Q2 FY27?
QMS Medical reported consolidated revenue of ₹52.52 crore for the quarter ended September 30, 2026, compared with ₹44.70 crore in Q2 FY26 and ₹56.87 crore in Q1 FY27. Revenue was therefore higher by 17.5% year on year but lower by 7.6% sequentially.
Operating profit was ₹6.52 crore, compared with ₹6.92 crore a year earlier and ₹8.31 crore in the June 2026 quarter. Profit before tax stood at ₹3.28 crore, while net profit was ₹2.44 crore. Earnings per share were ₹1.22, versus ₹1.61 in Q2 FY26 and ₹1.89 in Q1 FY27.
The board approved the unaudited standalone and consolidated results for the September quarter and half year on November 14, 2026. The company had earlier notified exchanges that its board would meet on that date to consider the results.
Why did QMS Medical's profitability weaken despite revenue growth?
QMS Medical's operating margin declined to 12.41% in Q2 FY27 from 15.48% in Q2 FY26 and 14.61% in Q1 FY27. Operating profit fell 5.7% year on year despite the rise in revenue, indicating that costs increased faster than sales during the quarter.
The quarterly financial data show expenses of ₹46.00 crore, compared with ₹37.78 crore in the year-ago period. Interest expense rose to ₹1.86 crore from ₹1.36 crore, while depreciation increased to ₹1.60 crore from ₹0.94 crore. These movements reduced the amount of operating profit that translated into profit before tax and net profit.
Net profit declined 31.8% year on year from ₹3.58 crore and 38.4% from ₹3.96 crore in the June quarter. The sequential comparison also reflects a lower revenue base and a 220-basis-point reduction in operating margin from Q1 FY27.
How does the Q2 result compare with QMS Medical's recent performance?
QMS Medical's Q2 revenue remained above the ₹44.42 crore recorded in Q4 FY26 and the ₹44.70 crore reported in Q2 FY26, but it did not sustain the ₹56.87 crore level reached in Q1 FY27. The September-quarter operating margin was also lower than the margins reported in the preceding four quarters.
In Q1 FY27, QMS Medical had reported revenue of ₹56.87 crore, operating profit of ₹8.31 crore and net profit of ₹3.96 crore. Q2 operating profit of ₹6.52 crore was down 21.5% quarter on quarter, while net profit was down 38.4%.
The company reported FY26 revenue from operations of ₹172.88 crore. In the June 2026 quarter, services accounted for 41% of revenue, underlining the significance of the services business to the group's operating mix.
Got a follow-up? Ask IRIS
What corporate actions has QMS Medical approved?
QMS Medical has approved a Composite Scheme of Arrangement to demerge its healthcare services business into Saarathi Healthcare. The disclosed proposal provides for a 1:1 share swap and a proposed listing of Saarathi Healthcare on the NSE, subject to the approvals required for the scheme.
The company has stated that the healthcare services business recorded revenue of ₹37.17 crore in FY26, representing about 24.41% of FY26 turnover. The board also approved the acquisition of BeamOptics Scientific. The available information does not provide financial terms or a completion date for that acquisition.
These actions are relevant for shareholders because the proposed separation would change QMS Medical's business structure. Until regulatory, shareholder and other required approvals are obtained, the demerger remains a proposed transaction rather than a completed restructuring.
What should investors assess after the Q2 FY27 numbers?
Investors will likely focus on whether QMS Medical can improve its operating margin after the Q2 decline to 12.41%. Revenue growth was positive year on year, but lower operating profit and higher interest and depreciation charges resulted in a sharper decline in net profit.
Management had indicated an FY27 top-line objective of around ₹220 crore, with scope for a revision after Q2 or Q3. It also expected patient support programmes to contribute ₹90 crore to ₹105 crore of revenue in FY27 and had indicated an aim for average EBITDA margins of around 16% to 20% by the end of FY27.
QMS Medical has scheduled an earnings conference call for November 17, 2026, at 11:30 AM IST. That discussion may provide additional context on the Q2 cost base, patient support programme execution, the proposed healthcare-services demerger and the stated full-year objectives.
Conclusion
QMS Medical delivered year-on-year revenue growth in Q2 FY27, but operating profit, margin and net profit declined. Revenue of ₹52.52 crore was 17.5% higher than a year earlier, while net profit of ₹2.44 crore was 31.8% lower, reflecting cost and margin pressure in the quarter.
The next items to watch are management's comments on the November 17 earnings call, progress against the around ₹220 crore FY27 revenue objective, and developments in the proposed demerger of the healthcare services business into Saarathi Healthcare.


